AGTC CEO Sue Washer told GEN the change will not hurt the development program, despite the start of the trial being pushed back a few months from AGTC’s earlier estimate of a planned launch by the end of 2020 . . .
AGTC Sets Sights on Late-Stage Retinitis Pigmentosa Gene Therapy Trial
In a three-way race to develop a gene therapy for X-linked RP, AGTC CEO Sue Washer says trial inception delay won’t hurt the development program.
Applied Genetic Technologies Corp. (AGTC) says it will launch its planned Phase II/III trial of its gene therapy candidate for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene, in the first quarter of 2021 [AGTC]
